Exelixis (EXEL) stock is in focus after the company reported first quarter 2026 results, maintained full year revenue guidance of US$2.525b to US$2.625b, and highlighted ongoing progress across its oncology pipeline.

The first quarter numbers, the confirmed 2026 revenue outlook and the fresh US$750m buyback sit against a 30 day share price return of 11.67% and a three year total shareholder return above 150%, suggesting momentum has been building rather than fading.

If Exelixis's oncology focus has your attention, it could be a good moment to scan for more opportunities in cancer and biotech related artificial intelligence through our 28 healthcare AI stocks

With the stock up 11.67% over the past month and more than 150% over three years, plus fresh buybacks and confirmed 2026 revenue guidance, the key question is whether Exelixis is still mispriced or if the market already recognises its future potential.

Most Popular Narrative: 5.5% Overvalued

With Exelixis last closing at $50.13 versus a narrative fair value of $47.53, the most followed model sees the stock trading a little ahead of its estimated worth using a 7.16% discount rate.

The company's substantial free cash flow, strong balance sheet, and disciplined capital allocation (including aggressive share repurchases and prioritization of high-probability, high-value R&D programs) position Exelixis to invest in next-generation discovery and strategic partnerships, which has the potential to improve operating leverage and net margins over time as the product portfolio scales.

Curious what kind of revenue path, earnings power and future P/E multiple sit behind that fair value, along with how much buybacks reshape per share numbers over time.

Result: Fair Value of $47.53 (OVERVALUED)

However, this narrative still leans heavily on CABOMETYX concentration and assumes pipeline assets clear clinical, competitive, and regulatory hurdles without materially weaker pricing or margins.

Another View: Market Ratios Point the Other Way

Analyst narratives and price targets suggest Exelixis is about 5.5% overvalued at $50.13 versus a fair value of $47.53. However, the current P/E of 15.1x looks low compared with the US Biotechs industry at 17.2x, peers at 23.3x, and a fair ratio of 19.3x.

If the market were to move closer to that fair ratio, pricing could look very different. The key question is whether current caution around growth and concentration risk keeps that gap in place or eventually closes it.

Next Steps

With a mix of optimism around rewards and caution on the risks, the picture is far from one sided. Move quickly and weigh the trade offs yourself by checking the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If Exelixis is on your radar, do not stop there. Widening your watchlist now could help you spot opportunities others overlook in the same amount of time.

• Target sturdy cash flows and balance sheet strength by reviewing companies in the solid balance sheet and fundamentals stocks screener (45 results).
• Hunt for quality at a possible discount by scanning the 51 high quality undervalued stocks.
• Spot earlier stage prospects with potential by checking the 28 elite penny stocks with strong financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.